期刊
FUTURE ONCOLOGY
卷 17, 期 6, 页码 637-647出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0937
关键词
combination therapy; LEAP program; lenvatinib; pembrolizumab; solid tumors
类别
资金
- Merck Sharp Dohme Corp.
- Bristol Myers Squibb
- Eisai Inc
- Merck Sharp Dohme
- Eisai Inc., Woodcliff Lake, NJ, USA
The combination therapy of lenvatinib plus pembrolizumab demonstrates robust antitumor activity and durable responses across diverse tumor types with a manageable safety profile, making it a potentially important new regimen for several solid cancers that currently have limited therapeutic options.
Tumor progression and immune evasion result from multiple oncogenic and immunosuppressive signals within the tumor microenvironment. The combined blockade of VEGF and inhibitory immune checkpoint signaling has been shown to enhance immune activation and tumor destruction in preclinical models. The LEAP clinical trial program is evaluating the safety and efficacy of lenvatinib (a multikinase inhibitor) plus pembrolizumab (a PD-1 inhibitor) across several solid tumor types. Preliminary results from ongoing trials demonstrate robust antitumor activity and durable responses across diverse tumor types with a manageable safety profile. Thus, lenvatinib plus pembrolizumab is anticipated to be an important potential new regimen for several solid cancers that currently have limited therapeutic options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据